Prader Willi Syndrome Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
Dallas, TX (PRWEB) February 13, 2015 -- The report “Prader-Willi Syndrome (PWS) – Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Prader-Willi Syndrome (PWS). Prader-Willi syndrome is a complex genetic condition. It is a rare disorder present at birth that results in a number of bodily, psychological and behavioral problems. Prader-Willi Syndrome occurs in approximately one out of every 15,000 births. Prader-Willi syndrome is caused by the thrashing of genes in a precise area of chromosome 15. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/prader-willi-syndrome-pws-pipeline-review-h1-2015-market-report.html .
The report also reviews key players involved in the therapeutic development for Prader-Willi Syndrome (PWS) and special features on late-stage and discontinued projects. Companies discussed in this Prader-Willi Syndrome (PWS) – Pipeline Review, H1 2015 report include Chong Kun Dang Pharmaceutical Corp., Essentialis, Inc., Ferring International Center S.A., LG Life Sciences, Ltd., P2D Bioscience, Pfizer Inc., Rhythm Pharmaceuticals.
The symptoms of Prader-Willi syndrome are mild to moderate intellectual impairment, learning disabilities, temper tantrums, stubbornness, sleep abnormalities and compulsive behavior. Drugs profile discussed in this report include beloranib, betahistine hydrochloride, diazoxide choline CR, FE-992097, NOX-B11, setmelanotide, somatropin SR. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269600 . (This is a premium report priced at US$2000 for a single user License.)
Featured News & Press Releases cover by this “Prader-Willi Syndrome (PWS) – Pipeline Review, H1 2015” report include: Nov 14, 2014: Essentialis To Present Clinical Update At The Annual Research Conference Of The Foundation For Prader-Willi Research; Oct 01, 2014: Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome; Jul 23, 2014: Essentialis Secures Foundation for Prader-Willi Research Grant to Help Advance DCCR in the Treatment of Prader-Willi Syndrome; Jul 10, 2014: Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Prader-Willi Syndrome; Jun 27, 2014: Essentialis Announces the Dosing of the First Patient in a Clinical Study of DCCR in Prader-Willi Syndrome; Jun 17, 2014: Essentialis Announces the Grant of its First Japanese Patent Which Provides Extensive Protection to DCCR in the Treatment of Prader-Willi Syndrome; May 28, 2014: Essentialis Obtains Orphan Drug Designation from FDA for DCCR in the Treatment of Prader-Willi Syndrome; Jan 15, 2014: Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome.
Table of content
List of Tables
Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2015
Number of Products under Development for Prader-Willi Syndrome (PWS) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Prader-Willi Syndrome (PWS) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015
Prader-Willi Syndrome (PWS) - Pipeline by Essentialis, Inc., H1 2015
Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center S.A., H1 2015
Prader-Willi Syndrome (PWS) - Pipeline by LG Life Sciences, Ltd., H1 2015
Prader-Willi Syndrome (PWS) - Pipeline by P2D Bioscience, H1 2015
Prader-Willi Syndrome (PWS) - Pipeline by Pfizer Inc., H1 2015
Prader-Willi Syndrome (PWS) - Pipeline by Rhythm Pharmaceuticals, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Prader-Willi Syndrome (PWS) Therapeutics - Recent Pipeline Updates, H1 2015
List of Figures
Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2015
Number of Products under Development for Prader-Willi Syndrome (PWS) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Explore more reports on TherapeuticsMarket at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.
Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article